Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EBIT (2017 - 2025)

VYNE Therapeutics' EBIT history spans 9 years, with the latest figure at -$7.5 million for Q2 2025.

  • For Q2 2025, EBIT rose 27.45% year-over-year to -$7.5 million; the TTM value through Jun 2025 reached -$42.6 million, down 38.12%, while the annual FY2025 figure was -$29.7 million, 31.83% up from the prior year.
  • EBIT reached -$7.5 million in Q2 2025 per VYNE's latest filing, up from -$9.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$5.9 million in Q1 2023 to a low of -$13.1 million in Q3 2024.
  • Average EBIT over 5 years is -$9.0 million, with a median of -$9.0 million recorded in 2021.
  • Peak YoY movement for EBIT: skyrocketed 94.29% in 2021, then plummeted 109.99% in 2024.
  • A 5-year view of EBIT shows it stood at -$8.8 million in 2021, then increased by 9.74% to -$8.0 million in 2022, then grew by 14.43% to -$6.8 million in 2023, then plummeted by 86.91% to -$12.8 million in 2024, then soared by 40.94% to -$7.5 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EBIT are -$7.5 million (Q2 2025), -$9.2 million (Q1 2025), and -$12.8 million (Q4 2024).